Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Updates Neurostim Guidance For Depression, Epilepsy

Executive Summary

Special arrangements are needed for VNS for treatment-resistant depression and DBS of the anterior thalamus for refractory epilepsy.

You may also be interested in...



LivaNova's Vagus Nerve Stimulator Earns CE Mark For Treating Depression

LivaNova announced its vagus nerve stimulator for depression earned the CE mark and said that marketing efforts will be limited in the EU and US.

Exec Chat: Signifier Medical Investing In ‘Daytime-Only Treatments’ And Diagnostics For Sleep Apnea

The UK-based company is seeking to raise a further $100m in 2021 following the recent US clearance of its first product, a daytime-use neurostimulation device for snoring and mild obstructive sleep apnea.

Cantel Medical Snapped Up By Steris For $3.6Bn

The deal combines two of the largest providers of sterilization and infection-prevention products to create a $4bn-plus-revenue business.

Topics

Related Companies

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel